Information  X 
Enter a valid email address

ValiRx PLC (VAL)

  Print      Mail a friend       Annual reports

Friday 09 February, 2018

ValiRx PLC

Issue of options and directors dealings

RNS Number : 4699E
ValiRx PLC
09 February 2018
 

 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

Issue of options and directors dealings

 

London, UK., 9 February 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces it has awarded options to directors and key management.  The options may be exercised at a price of 4 pence per share at any time up until 7 February 2028.

 

Name of Director

Number of Existing Options*

Option Award

Total number of Options

% of existing share capital

Oliver de Giorgio-Miller

555,000

2,750,000

3,305,000

0.8%

Dr Satu Vainikka

694,000

3,625,000

4,319,000

1.1%

Dr George Morris

597,000

3,125,000

3,722,000

0.9%

Gerry Desler

592,960

3,000,000

3,592,960

0.9%

Kevin Alexander

545,000

2,500,000

3,045,000

0.7%

Others

429,000

2,300,000

2,279,000

0.6%

Total

3,412,960

17,300,000

20,712,960

5.0%

*existing options are exercisable at a price between 43.125p - 125p

The issued share capital of the Company comprises 407,462,717 ordinary shares of 0.1 pence per shares. The table below illustrates the existing equity holdings of the directors:

Name of Director

Total number of shares

% of existing share capital

Oliver de Giorgio-Miller

59,555

0.015%

Dr Satu Vainikka

624,909

0.15%

Dr George Morris

588,287

0.14%

Gerry Desler

541,875

0.13%

Kevin Alexander

104,278

0.026%

Total

1,918,904

0.46%

 

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

[email protected]



Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray/Jo Turner/Richard Nash

Tel: +44 (0) 20 7213 0880



Beaufort Securities Limited (Broker)

Jon Belliss

Tel: +44 (0) 207 382 8300

 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Oliver de Giorgio-Miller

2

Reason for notification


a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx Plc

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Options over ordinary shares

 

ISIN: GB00BWWYSP41

b.

Nature of the transaction

 Grant of options

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


4p

2,750,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

2,750,000

 

4p

e.

Date of the transaction

9 February 2018

f.

Place of the transaction

AIM

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Dr Satu Vainikka

2

Reason for notification


a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx Plc

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Options over ordinary shares

 

ISIN: GB00BWWYSP41

b.

Nature of the transaction

 Grant of options

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


4p

3,625,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

3,625,000

 

4p

e.

Date of the transaction

9 February 2018

f.

Place of the transaction

AIM

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Dr George Morris

2

Reason for notification


a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx Plc

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Options over ordinary shares

 

ISIN: GB00BWWYSP41

b.

Nature of the transaction

 Grant of options

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


4p

3,125,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

3,125,000

 

4p

e.

Date of the transaction

9 February 2018

f.

Place of the transaction

AIM

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Gerry Desler

2

Reason for notification


a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx Plc

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Options over ordinary shares

 

ISIN: GB00BWWYSP41

b.

Nature of the transaction

 Grant of options

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


4p

3,000,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

3,000,000

 

4p

e.

Date of the transaction

9 February 2018

f.

Place of the transaction

AIM

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Kevin Alexander

2

Reason for notification


a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx Plc

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Options over ordinary shares

 

ISIN: GB00BWWYSP41

b.

Nature of the transaction

 Grant of options

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


4p

2,500,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

2,500,000

 

4p

e.

Date of the transaction

9 February 2018

f.

Place of the transaction

AIM

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAFANESSPEFF

a d v e r t i s e m e n t